Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types

Overexpression of the chondroitin sulfate proteoglycan 4 (CSPG4) has been associated with the pathology of multiple types of such as melanoma, breast cancer, squamous cell carcinoma, mesothelioma, neuroblastoma, adult and pediatric sarcomas, and some hematological cancers. CSPG4 has been reported to exhibit a role in the growth and survival as well as in the spreading and metastasis of tumor cells. CSPG4 is overexpressed in several malignant diseases, while it is thought to have restricted and low expression in normal tissues. Thus, CSPG4 has become the target of numerous anticancer treatment approaches, including monoclonal antibody-based therapies. This study reviews key potential anti-CSPG4 antibody and immune-based therapies and examines their direct antiproliferative/metastatic and immune activating mechanisms of action.

• Publication year

  2018

• Venue

  Frontiers in Immunology

• Publication date

  2018-01-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3389/fimmu.2017.01911PMID 29375561PMCID 5767725
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BRAF inhibitors: resistance and the promise of combination treatments for melanoma

  2017cited by this paper
• CSPG4: a prototype oncoantigen for translational immunotherapy studies

  2017cited by this paper
• The regulatory mechanisms of NG2/CSPG4 expression

  2017cited by this paper
• Human MAP Tau Based Targeted Cytolytic Fusion Proteins

  2017cited by this paper
• CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL

  2017cited by this paper
• Building blocks for institutional preparation of CTL019 delivery.

  2017influential reference
• NG2 Proteoglycan‐Dependent Contributions of Pericytes and Macrophages to Brain Tumor Vascularization and Progression

  2016cited by this paper
• A novel approach for targeted elimination of CSPG4‐positive triple‐negative breast cancer cells using a MAP tau‐based fusion protein

  2016influential reference
• Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand

  2016cited by this paper
• Targeted radioimmunotherapy of triple negative breast cancer with CSPG4-specific 212Pb-labeled monoclonal antibody.

  2016cited by this paper
• The Role of NG2 Proteoglycan in Glioma

  2016cited by this paper
• Mesenchymal Tumors Can Derive from Ng2/Cspg4-Expressing Pericytes with β-Catenin Modulating the Neoplastic Phenotype.

  2016cited by this paper
• The application of local hypobaric pressure — A novel means to enhance macromolecule entry into the skin

  2016cited by this paper
• The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma

  2015cited by this paper
• Radioimmunotherapy of human tumours

  2015cited by this paper
• Radioimmunotherapy of human tumours

  2015cited by this paper
• Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia

  2015cited by this paper
• Stonin1 mediates endocytosis of the proteoglycan NG2 and regulates focal adhesion dynamics and cell motility

  2015cited by this paper
• Theranostic Impact of NG2/CSPG4 Proteoglycan in Cancer

  2015cited by this paper
• NG2‐glia and their functions in the central nervous system

  2015cited by this paper
• Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma

  2014cited by this paper
• Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells

  2014cited by this paper
• Recombinant DNA Technology for Melanoma Immunotherapy: Anti-Id DNA Vaccines Targeting High Molecular Weight Melanoma-Associated Antigen

  2014cited by this paper
• Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer

  2014cited by this paper
• Expression of the chondroitin sulphate proteoglycan, NG2, in paediatric brain tumors.

  2014cited by this paper
• Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients

  2014cited by this paper
• Oligodendrocyte Precursor Cells Modulate the Neuronal Network by Activity-Dependent Ectodomain Cleavage of Glial NG2

  2014cited by this paper
• T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo

  2013cited by this paper
• NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion.

  2013cited by this paper
• High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer.

  2013cited by this paper
• Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy

  2013cited by this paper
• Proteoglycans and their roles in brain cancer

  2013cited by this paper
• Cell-Surface Expression of Neuron-Glial Antigen 2 (NG2) and Melanoma Cell Adhesion Molecule (CD146) in Heterogeneous Cultures of Marrow-Derived Mesenchymal Stem Cells

  2013cited by this paper
• IgG4 subclass antibodies impair antitumor immunity in melanoma.

  2013cited by this paper
• Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival

  2013cited by this paper
• The chrondroitin sulfate proteoglycan (CSPG4) regulates human trophoblast function.

  2013cited by this paper
• Abstract B65: IgG4 subclass antibodies impair antitumor immunity in melanoma.

  2013cited by this paper
• Oligodendrocyte progenitors balance growth with self-repulsion to achieve homeostasis in the adult brain

  2013cited by this paper
• General overview of radioimmunotherapy of solid tumors.

  2013cited by this paper
• Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells

  2012cited by this paper
• Abstract 2514: CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma

  2012influential reference
• CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma

  2011influential reference
• Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4.

  2011cited by this paper
• Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells

  2011cited by this paper
• Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma

  2011cited by this paper
• Redirected Lysis of Human Melanoma Cells by a MCSP/CD3-bispecific BiTE Antibody That Engages Patient-derived T Cells

  2011cited by this paper
• Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma.

  2011cited by this paper
• Molecular Network Associated with MITF in Skin Melanoma Development and Progression

  2011cited by this paper
• The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells

  2011influential reference
• CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.

  2010cited by this paper
• Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo

  2010cited by this paper
• Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen

  2010cited by this paper
• Selectins promote tumor metastasis.

  2010cited by this paper
• NG2, a member of chondroitin sulfate proteoglycans family mediates the inflammatory response of activated microglia.

  2010cited by this paper
• Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

  2010cited by this paper
• A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas.

  2010cited by this paper
• Functional and clinical relevance of chondroitin sulfate proteoglycan 4.

  2010cited by this paper
• The NG2 proteoglycan promotes oligodendrocyte progenitor proliferation and developmental myelination.

  2010cited by this paper
• New perspectives on APC control of cell fate and proliferation in colorectal cancer

  2009cited by this paper
• Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition.

  2009cited by this paper
• Human bone marrow mesenchymal cells express NG2: possible increase in discriminative ability of flow cytometry during mesenchymal stromal cell identification.

  2009cited by this paper
• NG2 expression predicts the metastasis formation in soft‐tissue sarcoma patients

  2009cited by this paper
• Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies

  2009cited by this paper
• FGF2-dependent neovascularization of subcutaneous Matrigel plugs is initiated by bone marrow-derived pericytes and macrophages

  2008cited by this paper
• Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways.

  2008cited by this paper
• Differential phosphorylation of NG2 proteoglycan by ERK and PKCα helps balance cell proliferation and migration

  2007cited by this paper
• Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A).

  2007cited by this paper
• Tumor-Reactive CD4+ T Cell Responses to the Melanoma-Associated Chondroitin Sulphate Proteoglycan in Melanoma Patients and Healthy Individuals in the Absence of Autoimmunity1

  2007cited by this paper
• A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation‐associated neurodegeneration

  2006cited by this paper
• Targeting Melanoma Cells with Human High Molecular Weight-Melanoma Associated Antigen-Specific Antibodies Elicited by a Peptide Mimotope: Functional Effects

  2006cited by this paper
• NG2 expression regulates vascular morphology and function in human brain tumours

  2006cited by this paper
• Molecular basis of interaction between NG2 proteoglycan and galectin‐3

  2006cited by this paper
• Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight‐melanoma associated antigen (HMW‐MAA) specific monoclonal antibody

  2005cited by this paper
• Vaccination with a Human High Molecular Weight Melanoma-Associated Antigen Mimotope Induces a Humoral Response Inhibiting Melanoma Cell Growth In Vitro1

  2005cited by this paper
• Morphological, immunocytochemical and flow cytometric in vitro characterisation of a surface-adherent medulloblastoma.

  2005cited by this paper
• High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells

  2005cited by this paper
• Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma.

  2005cited by this paper
• Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2.

  2005cited by this paper
• PKC- and PI3K-dependent but ERK-independent proliferation of murine splenic B cells stimulated by chondroitin sulfate B.

  2005cited by this paper
• Characterization of an ERK-binding Domain in Microphthalmia-associated Transcription Factor and Differential Inhibition of ERK2-mediated Substrate Phosphorylation*

  2005cited by this paper
• Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen

  2005cited by this paper
• NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin.

  2004cited by this paper
• Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms

  2004influential reference
• NG2 Proteoglycan Promotes Endothelial Cell Motility and Angiogenesis via Engagement of Galectin-3 and α3β1 Integrin

  2004cited by this paper
• Phosphorylation of NG2 Proteoglycan by Protein Kinase C-α Regulates Polarized Membrane Distribution and Cell Motility*

  2004cited by this paper
• Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance.

  2004cited by this paper
• Malignant fibrous histiocytoma: a proposed cellular origin and identification of its characterizing gene transcripts.

  2003cited by this paper
• Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10−/CD24−/CD65s+/CD15+ B-cell phenotype

  2003cited by this paper
• Expression of NG2 proteoglycan during endochondral and intramembranous ossification

  2003cited by this paper
• Role of melanoma chondroitin sulphate proteoglycan in patterning stem cells in human interfollicular epidermis

  2003cited by this paper
• The microphthalmia transcription factor (MITF) contains two N‐terminal domains required for transactivation of osteoclast target promoters and rescue of mi mutant osteoclasts

  2002cited by this paper
• Hyaluronic Acid and Chondroitin Sulphate A Rapidly Promote Differentiation of Immature DC with Upregulation of Costimulatory and Antigen‐Presenting Molecules, and Enhancement of NF‐κB and Protein Kinase Activity

  2002cited by this paper
• Effect of chondroitin sulfate on murine splenocytes sensitized with ovalbumin.

  2002cited by this paper
• Glycosaminoglycans are a potential cause of rheumatoid arthritis

  2002cited by this paper
• NG2 Is a Major Chondroitin Sulfate Proteoglycan Produced after Spinal Cord Injury and Is Expressed by Macrophages and Oligodendrocyte Progenitors

  2002cited by this paper
• NG2 proteoglycan mediates β1 integrin‐independent cell adhesion and spreading on collagen VI

  2002cited by this paper
• Melanoma Chondroitin Sulfate Proteoglycan Regulates Matrix Metalloproteinase-dependent Human Melanoma Invasion into Type I Collagen*

  2001cited by this paper
• Transient expression of the NG2 proteoglycan by a subpopulation of activated macrophages in an excitotoxic hippocampal lesion

  2001cited by this paper
• Glioma classification: a molecular reappraisal.

  2001cited by this paper
• The multi‐PDZ domain protein MUPP1 is a cytoplasmic ligand for the membrane‐spanning proteoglycan NG2

  2000cited by this paper

• Profiling of Extracellular Vesicles of Non‐Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance

  2026cites this paper
• Decoding the Cellular Heterogeneity and Malignant Progression of Human Penile Squamous Cell Carcinoma by Single‐Cell RNA Sequencing

  2026cites this paper
• Enhanced diagnostic potential of CSPG4 in melanoma and nevi: a comparative study with PRAME, CDC7 and Ki67

  2025cites this paper
• Coarse-grained Martini 3 model of chondroitin sulfate A

  2025cites this paper
• Advances and Challenges in Pluripotent Stem Cell‐Based Whole‐Cell Vaccines for Cancer Treatment

  2025cites this paper
• Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research

  2025cites this paper
• IgE based therapeutics are an emerging modality in cancer treatment

  2025cites this paper
• Chondroitin sulfate proteoglycan 4 (CSPG4) overexpression as an oncogenic driver and prognostic marker for unfavorable outcomes in hepatocellular carcinoma

  2025cites this paper
• Exploring Emerging Therapeutic Targets in Osteosarcoma by Revisiting the Immune and Cancer-Intrinsic Hallmarks of Cancer

  2025cites this paper
• Proteoglycans in Breast Cancer: Friends and Foes

  2025cites this paper
• Chemical composition, antioxidant properties and cytotoxic potential of Leea macrophylla extracts: insights from molecular docking and pharmacokinetic analysis.

  2025cites this paper
• MEPACRINE: A CANDIDATE CSPG4 TARGETED TREATMENT IN CANCER

  2025cites this paper
• Relevance of AKT and RAS Signaling Pathways for Antibody–Drug Conjugate Immunotherapies in Acute Lymphoblastic Leukemia

  2025cites this paper
• Camptothecin-loaded chondroitin sulfate-celecoxib reduction-sensitive micelles for enhanced colon cancer treatment.

  2025cites this paper
• Endosialin-directed CAR-T cell therapy: A promising approach for targeting triple-negative breast cancer.

  2025cites this paper
• Evaluating CSPG4 expression in esophageal basaloid squamous cell carcinoma and conventional squamous cell carcinoma: a multi-institutional retrospective study in China.

  2025cites this paper
• Computational analysis of the structural-functional dynamics of a Co-receptor proteoglycan

  2025cites this paper
• Identification of distinct profiles of glioblastoma through the immunocapture of extracellular vesicles from patient plasma

  2025cites this paper
• Human CSPG4-targeting CAR-macrophages inhibit melanoma growth

  2025influential citation
• Functional aptamer evolution-enabled elucidation of a melanoma migration-related bioactive epitope

  2025cites this paper
• Chondroitin Sulfate: An Ideal Biomaterial based Scaffolds for Cartilage Regeneration and Its Therapeutic Potential

  2025cites this paper
• B7-H3 and CSPG4-targeted CAR T cells as potent effectors in anaplastic thyroid cancer

  2025cites this paper
• Diagnostic potential of exosomal extracellular vesicles in oncology

  2024cites this paper
• Identification of anoikis-related molecular patterns and the novel risk model to predict prognosis, tumor microenvironment infiltration and immunotherapy response in bladder cancer

  2024cites this paper
• Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms

  2024cites this paper
• Macrophages producing chondroitin sulfate proteoglycan‐4 induce neuro‐cardiac junction impairment in Duchenne muscular dystrophy

  2024cites this paper
• Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma

  2024influential citation
• Chondroitin sulfate proteoglycan 4 (CSPG4) increases invasion of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma by modifying TGFβ signaling.

  2024cites this paper
• Pseudogene CSPG4P12 inhibits colorectal cancer progression by attenuating epithelial-mesenchymal transition

  2024cites this paper
• Unveiling heterogeneity in MSCs: exploring marker-based strategies for defining MSC subpopulations

  2024cites this paper
• Cancer therapy with antibodies

  2024cites this paper
• Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy

  2024cites this paper
• Prospects and challenges of CAR-T in the treatment of ovarian cancer.

  2024cites this paper
• Cloning and Characterization of a Novel N-Acetyl-D-galactosamine-4-O-sulfate Sulfatase, SulA1, from a Marine Arthrobacter Strain

  2024cites this paper
• The Tumor Microenvironment and Immune Response in Breast Cancer

  2024cites this paper
• The application of radionuclide therapy for breast cancer

  2024cites this paper
• Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer

  2023cites this paper
• CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer

  2023cites this paper
• MiR126-targeted-nanoparticles combined with PI3K/AKT inhibitor as a new strategy to overcome melanoma resistance

  2023cites this paper
• The hydrophobic cluster on the surface of protein is the key structural basis for the SDS-resistance of chondroitinase VhChlABC

  2023influential citation
• CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma

  2023cites this paper
• Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma

  2023cites this paper
• Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors

  2023cites this paper
• CHST11-modified chondroitin 4-sulfate as a potential therapeutic target for glioblastoma.

  2023cites this paper
• Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma

  2023cites this paper
• Immunotherapy of gastrointestinal stromal tumors: current view and future directions

  2023cites this paper
• Potential Promises and Perils of Human Biological Treatments for Immunotherapy in Veterinary Oncology

  2023cites this paper
• Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4

  2023cites this paper
• Real-time in vivo cancer staging of nasopharyngeal carcinoma patients with rapid fiberoptic Raman endoscopy.

  2023cites this paper
• The participation of tumor residing pericytes in oral squamous cell carcinoma

  2023cites this paper
• The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer

  2023cites this paper
• Metabolic pathways of potential miRNA biomarkers derived from liquid biopsy in epithelial ovarian cancer

  2023cites this paper
• A chimeric human/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma.

  2023cites this paper
• Establishment and validation of a plasma oncofetal chondroitin sulfated proteoglycan for pan-cancer detection

  2023cites this paper
• VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen

  2023cites this paper
• Chondroitin Sulfate Proteoglycan 4 as a Marker for Aggressive Squamous Cell Carcinoma

  2022cites this paper
• CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response

  2022cites this paper
• Structural dynamics of receptor recognition and pH-induced dissociation of full-length Clostridioides difficile Toxin B

  2022cites this paper
• Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape

  2022cites this paper
• The Study of Disease Mechanisms Based on Cascading Failure

  2022cites this paper
• Matrix Proteoglycans in Tumor Inflammation and Immunity.

  2022cites this paper
• Urbanization drives adaptive evolution in a Neotropical bird

  2022cites this paper
• A newly defined basement membrane-related gene signature for the prognosis of clear-cell renal cell carcinoma

  2022cites this paper
• Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial

  2022cites this paper
• CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response

  2022cites this paper
• Investigation of the effects of downregulation of jumping translocation breakpoint (JTB) protein expression in MCF7 cells for potential use as a biomarker in breast cancer.

  2022cites this paper
• Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells

  2022cites this paper
• Renewable marine polysaccharides for microenvironment-responsive wound healing.

  2022cites this paper
• CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil

  2022influential citation
• Current Developments in the Preclinical and Clinical use of Natural Killer T cells

  2022cites this paper
• Intracellular and Extracellular Markers of Lethality in Osteogenesis Imperfecta: A Quantitative Proteomic Approach

  2021cites this paper
• Acidic and Hypoxic Microenvironment in Melanoma: Impact of Tumour Exosomes on Disease Progression

  2021cites this paper
• Network-Based Analysis to Identify Drivers of Metastatic Prostate Cancer Using GoNetic

  2021cites this paper
• Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy

  2021cites this paper
• Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma

  2021cites this paper
• Preparation and Characterization of Sodium Alginate/Chitosan Composite Nanoparticles Loaded with Chondroitin Sulfate

  2021cites this paper
• Internalization and trafficking of CSPG-bound recombinant VAR2CSA lectins in cancer cells

  2021cites this paper
• In vivo trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart

  2021cites this paper
• A chondroitin sulfate proteoglycan 4-specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model

  2021cites this paper
• Low-density lipoprotein receptor-related protein 1 is a CROPs-associated receptor for Clostridioides infection toxin B

  2021cites this paper
• CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer

  2021cites this paper
• CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer

  2021cites this paper
• In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL

  2021cites this paper
• Human placental villous stromal extracellular matrix regulates fetoplacental angiogenesis in severe fetal growth restriction.

  2021cites this paper
• CK2 Activity Mediates the Aggressive Molecular Signature of Glioblastoma Multiforme by Inducing Nerve/Glial Antigen (NG)2 Expression

  2021cites this paper
• CHPF promotes malignancy of breast cancer cells by modifying syndecan-4 and the tumor microenvironment.

  2021cites this paper
• The emerging role of the chondroitin sulfate proteoglycan family in neurodegenerative diseases

  2021cites this paper
• Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF

  2021cites this paper
• 203/212Pb theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer.

  2020cites this paper
• Advanced Research of Chondroitin Sulfate and Its Derivatives in the Medicine Field

  2020cites this paper
• Monosomy 3 Influences Epithelial-Mesenchymal Transition Gene Expression in Uveal Melanoma Patients; Consequences for Liquid Biopsy

  2020cites this paper
• IgE Antibodies against Cancer: Efficacy and Safety

  2020cites this paper
• Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer

  2020cites this paper
• The Transcriptomic Analysis of NSC-34 Motor Neuron-Like Cells Reveals That Cannabigerol Influences Synaptic Pathways: A Comparative Study with Cannabidiol

  2020cites this paper
• CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes

  2020cites this paper
• In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update

  2020cites this paper
• Tumor Microenvironment: Extracellular Matrix Components – Part B

  2020cites this paper
• Chondroitin Sulphate Proteoglycans in the Tumour Microenvironment.

  2020cites this paper
• The Role of Proteoglycans in Cancer Metastasis and Circulating Tumor Cell Analysis

  2020cites this paper
• A Head Start: CAR-T Cell Therapy for Primary Malignant Brain Tumors

  2020cites this paper